Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Algernon Pharmaceuticals Inc (AGNPF)

Algernon Pharmaceuticals Inc (AGNPF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AGNPF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.0927 +43.68%
on 05/02/22
4.7500 -6.45%
on 04/19/22
-0.2063 (-4.44%)
since 04/14/22
3-Month
3.0927 +43.68%
on 05/02/22
5.0845 -12.60%
on 04/06/22
-0.5723 (-11.41%)
since 02/17/22
52-Week
2.5000 +77.75%
on 12/06/21
14.1200 -68.53%
on 06/04/21
-9.4563 (-68.03%)
since 05/17/21

Most Recent Stories

More News
Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program

VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO)...

AGN.CN : 5.900 (-1.67%)
AGNPF : 4.4437 (+6.05%)
Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

VANCOUVER, British Columbia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO)...

AGN.CN : 5.900 (-1.67%)
AGNPF : 4.4437 (+6.05%)
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis

VANCOUVER, British Columbia, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW)...

AGNPF : 4.4437 (+6.05%)
AGN.CN : 5.900 (-1.67%)
AGNPD : 3.2600 (-5.51%)
Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

VANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO)...

AGN.CN : 5.900 (-1.67%)
AGNPF : 4.4437 (+6.05%)
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 5.900 (-1.67%)
AGNPF : 4.4437 (+6.05%)
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

VANCOUVER, British Columbia, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 5.900 (-1.67%)
AGNPF : 4.4437 (+6.05%)
Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial

VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW)...

AGNPF : 4.4437 (+6.05%)
AGN.CN : 5.900 (-1.67%)
AGNPD : 3.2600 (-5.51%)
Algernon Pharmaceuticals Announces New Chief Financial Officer

VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW)...

AGNPF : 4.4437 (+6.05%)
AGN.CN : 5.900 (-1.67%)
AGNPD : 3.2600 (-5.51%)
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study

VANCOUVER, British Columbia, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW)...

AGN.CN : 5.900 (-1.67%)
AGNPF : 4.4437 (+6.05%)
Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (“Algernon” or the “Company”) (CSE: AGN) (FRANKFURT: AGW)...

AGN.CN : 5.900 (-1.67%)
AGNPF : 4.4437 (+6.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 4.4437
2nd Resistance Point 4.4437
1st Resistance Point 4.4437
Last Price 4.4437
1st Support Level 4.4437
2nd Support Level 4.4437
3rd Support Level 4.4437

See More

52-Week High 14.1200
Fibonacci 61.8% 9.6812
Fibonacci 50% 8.3100
Fibonacci 38.2% 6.9388
Last Price 4.4437
52-Week Low 2.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar